Hodgkin Lymphoma (NHL) (BIANCA)



Subscribe to be notified of changes or updates to this page.

3 + 2 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.

This purpose of this study is to determine the efficacy and safety of tisagenlecleucel (also referred to as CTL019, or Kymriah™) in children, adolescents and young adults with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL). The study is enrolling children and young adults up to age 25 with CD19-expressing mature B-cell NHL, including Burkitt leukemia/lymphoma, that has relapsed after one or more prior therapies or is primary refractory (not achieved a complete remission (CR) or partial response (PR) after the first line of therapy). This study involves the administration of the study drug, blood draws, assessment of lymphoma response, and chart reviews. After a process called leukapheresis, in which T cells (a type of white blood cell) are removed from the subject's blood and modified in order to target the lymphoma, they are returned back to the subject as the study drug. Reimbursement for travel may be provided. If you have questions or would like to learn more about the study, please contact the Cancer Immunotherapy Program at (215) 425-7193. The Principal Investigator is Dr. Shannon Maude.

Who Do I Contact?

If you are interested in participating in the study or want to learn more please contact our study team at mcbridee [at] chop.edu or 215-425-7193.

Eligibility & Criteria

IRB #:
Official Title:
A Phase II, Single Arm, Multicenter Open Label Trial To Determine The Safety and Efficacy of Tisagenlecleucel in Pediatric Patients with Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma (NHL) (BIANCA)
Study Phase:
Phase II
Eligible Age Range:
0 - 25 Years
Study Categories: